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Abstract
Objectives—Cervical cancer patients are at high risk for emotional distress. In this study we 
evaluate the PROMIS Emotional Distress-Depression and -Anxiety Short Forms for assessing 
depression and anxiety in a cervical cancer population.
Methods—A 15-item questionnaire was used in a cervical cancer biobehavioral randomized 
clinical trial, testing psychosocial telephone counseling (PTC) against usual care (UC). It was 
administered to 204 patients prior to randomization, four months post-enrollment, and nine 
months post-enrollment, together with legacy measures of depression. The short forms were 
evaluated in patients participating in this study over three time points for internal consistency, 
convergent validity, and responsiveness to change over time.
Results—Overall, 45% and 47% of patients scored in the moderate to severe range for anxiety 
and depression, respectively. Internal consistency coefficients were ≥0.95 at baseline, 4 months, 
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and 9 months for depression and anxiety. The average inter-item correlation was 0.65 and 0.73 at 
baseline assessment for depression and anxiety, respectively. The depression short form T-score 
was correlated with legacy distress scales ranging from 0.44–0.76, and the anxiety short form 
ranging from 0.45–0.78. The depression short form demonstrated sensitivity to change as patients 
randomized to the counseling intervention reported greater improvement over time in depression 
(p=0.014), and a nonsignificant improvement in anxiety, compared to the patients receiving usual 
care.
Conclusions—The PROMIS depression and anxiety short forms reliably and validly assess 
cervical cancer-specific emotional distress, capture salient features of distress in this population, 
and perform as well or better than legacy measures.
Keywords
patient-reported outcomes; cervical cancer; depression; anxiety
Introduction
Cervical cancer survivors experience quality of life (QOL) disruptions which are often 
severe and prolonged [1–3]. This disruption can include compromised emotional well-being 
[4–6]. The majority of clinical studies that assess QOL in cervical cancer patients generally 
report changes over time in physical, functional, or symptom-specific concerns [7–9], 
without specific reference to emotional well-being or distress. It is notable however, that in 
2014 the American Society of Clinical Oncology (ASCO) issued guidelines reinforcing the 
need to care for psychological needs of cancer survivors, specifically recommending that all 
people who have been treated for cancer be evaluated for symptoms of depression and 
anxiety. This premise is contained in Quality Oncology Practice Initiative (QOPI) 
certification, which recognizes that a patient’s emotional well-being should be assessed and 
documented in the chart, thereby demonstrating commitment to delivering the highest 
quality of cancer care.
Emotional distress may well deserve even greater attention in the context of cervical cancer 
care and survivorship, since distress in this population is frequently associated with 
advanced disease, long-term treatment sequelae, and lower socioeconomic status [6, 10, 11], 
and is likely to be associated with poor treatment compliance [12, 13]. PROMIS emotional 
distress short forms have previously been noted to reliably and validly assess depression and 
anxiety in several disease contexts [14–19]. Moreover, a cancer-specific PROMIS module 
has been created [20] which incorporates the emotional distress short forms and has shown 
to converge with expert clinical judgement [21], be appropriate in a variety of cancer settings 
[22] and several different modes of administration [23].
Results from a biobehavioral randomized trial demonstrated an improvement in emotional 
distress, as measured by PROMIS short forms of depression and anxiety, among cervical 
cancer patients randomized to a psychosocial telephone counseling (PTC) intervention, 
compared to those who received usual care [25]. The improvement was most evident 
between the baseline and four-month assessment interval, which coincided with ‘active 
treatment.’ These study results helped to reaffirm the importance of addressing emotional 
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distress in the cervical cancer population; second, they indicated that emotional distress is 
amenable to change and improvement; and third, they demonstrated that use of a 
psychometrically sound measure of distress, appropriate to the sociodemographic and 
disease characteristics of this population, can provide a robust and significant contribution to 
study and treatment planning. The evaluation of psychometric properties and performance of 
the PROMIS emotional distress short forms administered in this randomized trial [25] is the 
subject of the current report, and adds to the body of literature noting the importance of 
emotional well-being measurement among cervical cancer patients.
Materials and Methods
Study population
Our biobehavioral study sought to determine if the use of PTC could improve patient-
reported outcomes, compared to usual care. Primary and secondary objectives, patient 
eligibility, recruitment and retention, and details of PTC administration and results were 
previously published [5, 25]. Survivors of cervical cancer were identified from the California 
Cancer Registries (Orange, Los Angeles, Imperial, and San Diego Counties). Eligibility 
criteria were 1) stage 1 to IVA cervical cancer (locally advanced but without disseminated 
metastasis), 2) completion of definitive treatment at least 2 months earlier, and 3) ability to 
speak and read English or Spanish. Exclusion criteria were 1) treatment with biologic 
response modifiers or prior immunotherapy within 4 weeks of study enrollment, 2) treatment 
with investigational drugs within 30 days, 3) required corticosteroids, and 4) 
immunosuppression. After passive physician approval for contact, eligible survivors were 
contacted via mail and telephone. Participants were enrolled in the trial at ≥ 9 and less than 
30 months from diagnosis. All patients provided informed consent consistent with all 
federal, state and local requirements prior to enrolling in the study.
Patients were stratified based on language preference (English or Spanish) and randomly 
allocated to PTC or usual care. The PTC counseling intervention was, in general, conducted 
weekly for five weeks with a one-month booster session. The short-term outcome was 
assessed four months after study enrollment. A longer-term outcome was assessed nine 
months after study enrollment.
Measures
PROMIS Emotional Distress Short Forms.—The PROMIS emotional distress short 
forms (SF) consist of 15 items, 8 items on depression (Depression – Short Form 8a) and 7 
items on anxiety (Anxiety – Short Form 7a). PROMIS measures were developed, beginning 
in 2004, out of a collaborative process funded by the National Institutes of Health (NIH) 
Roadmap for Medical Research Initiative [26]. Mental health (along with physical 
functioning, fatigue, pain, and social participation) was identified as a core patient-reported 
outcome early in the development process. Using expert review and quantitative analysis of 
existing data, the PROMIS steering committee identified emotional distress as a key domain 
of mental health, and defined its three subdomains as depression, anxiety, and anger. 
Depression was defined as “low levels of positive affect,” anxiety as “autonomic arousal and 
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experience of threat,” and anger as “hostility,” “cynicism,” and “frustration” regarding 
“goal-directed behavior” [27].
Each item in the PROMIS emotional distress SF was scored from 1 to 5 points where 
1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. Consistent with PROMIS scoring 
convention, the scale score was computed using proration when more than 50% of items 
were answered. A high score on these PROMIS short forms connotes more emotional 
distress (i.e., more depression or anxiety). With a standardized normative T-score of 50 and a 
standard deviation of 10, T-scores <55 would translate as normal; 55–60 as mild; 60–70 as 
moderate, and ≥70 as severe distress [28].
Legacy Measures.—PROMIS short form scales are substantially shorter, and thus may 
confer an advantage over many legacy measures. The following legacy measures were 
included in this study to demonstrate relationships between PROMIS depression and anxiety 
short-form scales and legacy measures which could be related to mood.
The Functional Assessment of Cancer Therapy-Cervical (FACT-Cx) is a multidimensional, 
combined generic and disease-specific QOL questionnaire for cervical cancer patients. The 
FACT-G (general) questionnaire (version 4) is a 27-item self-report measure developed 
specifically for cancer patients and designed for use in a variety of settings [29]. It consists 
of four subscales (physical well-being (PWB), social well-being (SWB), emotional well-
being EWB), functional well-being (FWB)) that can be analyzed separately or summed to 
produce a total QOL score. Eleven additional items represent cervical cancer-specific 
problems. The FACT Trial Outcome Index (FACT-TOI) is the sum of the FACT subdomains 
PWB, FWB and cancer-specific concerns. The Brief Symptom Inventory (BSI-18) [30] is a 
shortened version of the BSI, developed to assess psychological distress. Each item is rated 
on a 5-point Likert scale from 0 (not at all) to 4 (always). Patients are asked to respond to 
each item in terms of “how they have been feeling during the past 7 days.” The BSI-18 
includes subscales measuring depression, anxiety, and somatization, as well as an overall 
total score.
The Impact of Event Scale (IES) [31] is a 15-item Likert scale to measure distress related to 
cancer. The IES has two sub-scales: (a) intrusive thoughts and feelings, and (b) avoidance of 
thoughts and feelings related to the stressful situation. The 10-item Perceived Stress Scale 
(PSS) assesses perceptions of stress over the past month [32] [33]. Items reflect how 
frequently the patient experienced a specific feeling/state, and are rated on a 5-point Likert 
scale (0=never to 4=very often). The Medical Outcomes Survey Social Support (MOS-SS) 
questionnaire, a 19-item multidimensional, self-administered survey of social support was 
developed for the Medical Outcomes Survey for patients with chronic conditions [34]. 
Responses are ranked on a Likert scale from 1 (none of the time) to 5 (all of the time), and 
indicate how often respondents perceive the availability of a particular source of support.
Patient Reported Assessments
Surveys were mailed in advance, with follow-up phone calls as needed. Patients completed 
PROs prior to randomization and at the 4- and 9-month assessment intervals by rating the 
accuracy of statements concerning signs and symptoms for the previous 7 days in the case of 
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PROMIS, FACT-Cx, BSI, and IES; for the past month in the case of PSS; and in general in 
the case of MOS-SS. Legacy measure properties can be found in Table 1. PROMIS 
emotional distress short form properties can be found in Table 2.
Statistical Considerations
Reliability.—The standardized Cronbach’s alpha coefficient was used to assess the internal 
consistency of the PROMIS short forms. Coefficients are generally regarded as acceptable if 
they are above 0.7, good if above 0.8, and excellent if above 0.9 [35].
Convergent Validity.—Convergent validity was examined for correlations between items 
using Spearman correlations due to the ordinal nature of item scores (1 to 5). Correlations 
between items and total raw scores were calculated after excluding the item from the total 
score. Agreement between the short form and other legacy measures of psychosocial distress 
as well as quality of life and social support, was estimated using Pearson correlation 
coefficients between T-score values and legacy measures.
Responsiveness to Change over Time.—The sensitivity of the short forms to change 
over time, including responsiveness to PTC, was examined with paired t-tests for the change 
in depression and anxiety scores from baseline to the 4-month assessment among the 
patients who completed both baseline and 4 month assessment in both PTC and control 
arms. It was hypothesized that emotional distress would decrease significantly for the 
counseled patients, compared to those receiving usual care. Effect sizes were calculated as 
the difference in change over time between arms divided by the standard deviation.
Results
Patient Characteristics
Between September 2008 and November 2011, 204 eligible patients were randomly 
allocated to receive either PTC (n=115) or usual care (UC) (n=89). The majority of patients 
were non-Hispanic white (51%), 41% were Hispanic, and 8% were Asian, African American 
or native American. Seventy-five percent (154/204, including 87 PTC and 67 UC) completed 
all questionnaires in English while 25% (n=50) completed questionnaires in Spanish. The 
mean age was 44.7 years. At diagnosis, 72% of patients were stage I, 12% stage II, 14% 
stage III-IVa and 2% unknown stage. Table 3 describes the sociodemographic characteristics 
of the study population. Psychometric results are reported based on combined study 
treatment arms (PTC and UC), for patients who completed the PROMIS measures at 
baseline for reliability and validity, with study treatment arms separately for responsiveness 
to change.
Assessment Completion
Completion rates for PROMIS measures were 99.5% for baseline (n=203), 82% (n=166) at 
the four-month assessment and 74% (n=151) at 9 months. Ninety-six percent of 
questionnaires (196) provided valid answers for all PROMIS items; 6 questionnaires had 1 
missing item and 1 had 2 missing items. Ninety-nine percent of questionnaires provided 
valid answers for legacy questionnaires (i.e., FACT-Cx, BSI, IES, PSS, MOS-SS). The 
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primary reasons for not completing assessments was loss to follow-up (25% PTC, 6% UC) 
with 1% of patients providing insufficient answers on the questionnaire.
Internal Consistency
The standardized Cronbach’s coefficient (Cronbach’s alpha) was calculated to evaluate the 
internal consistency of the 8 item PROMIS short form Depression, and the 7 item PROMIS 
short form Anxiety. At baseline, 4-month and 9-month assessments, Cronbach’s alpha 
coefficients were 0.95, 0.95 and 0.96 for Depression and 0.96, 0.95 and 0.95 for Anxiety, 
indicating excellent internal consistency.
Convergent Validity
The convergent validity of the PROMIS short forms was assessed by calculating the 
Spearman rank correlation coefficient between items. All correlation coefficients between 
PROMIS short form items and with legacy scales at baseline can be found in Tables 4–5. 
The average inter-item correlation at baseline was 0.65 for Depression and 0.73 for Anxiety; 
item-total correlations (calculated after exclusion of the item from the total) ranged from 
0.74–0.89. Item correlations with other scales including the FACT-Cx, PWB, SWB, EWB, 
FWB, Additional Concerns subscale, FACT-TOI , and MOS-SS were negative and ranged 
from −0.39 to −0.62 while correlations with the BSI, IES and PSS were positive and ranged 
from 0.44 to 0.76. For Anxiety, item correlations with legacy measures ranged from −0.29 to 
−0.59 for the FACT measures and MOS-SS and from 0.33 to 0.68 for the BSI, IES and PSS. 
Within the range of moderate to strong correlations, the strongest correlations between 
PROMIS T-scores and legacy scores were with the BSI subdomain standard scores for 
Depression and Anxiety, the BSI-GSI standard score and the PSS (0.78, 0.70 and 0.64 for 
the Depression T-score and 0.65, 0.61 and 0.60 for the Anxiety T-score).
Responsiveness to Change over Time
Sensitivity or responsiveness to change over time includes an ability to detect clinically 
relevant differences that may exist after patients received treatments, and between patients 
receiving different treatments. In the absence of disease recurrence, it was hypothesized that 
quality of life would improve over time as patients were further removed from cancer 
treatment, potentially independent of PTC vs UC. Therefore, it was also expected that 
patients’ depression and anxiety would also improve over time. Further, we hypothesized 
that those receiving PTC would improve at a more significant rate than those randomized to 
usual care. Thus, usual care patients were considered a reference group for evaluating the 
short forms’ sensitivity to treatment differences. While baseline scores were similar for PTC 
and UC, at the four-month assessment interval, PTC patients reported significantly greater 
improvement in depression compared to UC patients (mean change=−3.1 in PTC vs. −0.6 in 
UC adjusted for age and baseline value, p=0.014) [25]. This improvement approached a 
clinically meaningful increase (considered to be 3–5 points [36]). PTC patients also showed 
greater improvement in anxiety, but the difference did not reach statistical significance 
(mean change = −3.0 in PTC vs. −0.9 in UC adjusted for age and baseline level, p=0.068).
Changes over time in the BSI-18 depression and anxiety subscales, legacy measures that are 
also standardized to mean 50 and SD 10, were similar in PTC and UC arms. Effect sizes 
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were comparable between the PROMIS, BSI and PS measures (0.25, 0.21 and 0.24 
respectively for depression/stress change at 4 months; 0.13, 0.17 and 0.14 respectively for 
depression/stress at 9 months). Effect sizes for change in anxiety on PROMIS and BSI 
measures were 0.22 and 0.21 at 4 months, and 0.12 and 0.19 for anxiety at 9 months. Effect 
sizes for PROMIS, BSI and PS measures were larger than for other legacy measures 
including the FACT-Cx, FACT-TOI, FACT-EWB and IES (range: 0.02–0.14). English and 
Spanish speakers experienced similar decreases in depression and anxiety over time in both 
arms with no statistically significant differences (p>0.5).
Change over time was also assessed by comparing the number and proportion of patients 
retained reporting clinically meaningful depression (T-score≥55) across follow-up intervals 
(Table 6). Among those who remained in the study, the number with depression T-scores>55 
decreased by 14% for PTC and by 12% for UC at the 9-month follow-up. Numbers with 
clinically meaningful anxiety also decreased over time in both arms but to a smaller degree. 
Notably, the baseline scores of moderate to severe depression from the total sample (N=203) 
were 48/114 (42%) of PTC and 44/89 (49%) of UC, and those scoring in the moderate to 
severe anxiety range were 52/114 (46%) of PTC and 44/89 (49%) of UC. Correlations for 
change in PROMIS short form scores with change in scores for select legacy measures are 
presented in Table 6.
Discussion
We administered the PROMIS depression (8 items) and anxiety (7 items) short forms to 
cervical cancer patients participating in a biobehavioral clinical trial. We found that the 
PROMIS depression and anxiety short forms reliably and validly assess emotional distress in 
cervical cancer patients, are responsive to change, and perform as well or better than legacy 
measures. This conclusion supports the re-emphasis and growing body of oncology literature 
acknowledging the importance of screening for emotional distress in cancer patient 
populations, and the need to do so in a manner which can ultimately be integrated into the 
health care system with little burden [24].
Our results, specific to cervical cancer, provide additional PROMIS validation for its use in 
specific cancer patient populations. For example, in a recent large, US population-based 
sample of patients with recently diagnosed cancer, T-score reference values were identified 
which could help facilitate interpretation of the PROMIS domain scores in research studies 
or in clinical applications [36]. As previously noted, many of these factors, including 
emotional distress, which contribute to overall poor QoL are amenable to supportive care 
interventions and should be evaluated at the time of primary treatment [5]. While the 
prevalence of depression among cancer patients varies considerably in the literature, these 
estimates range from 15 – 40% [37, 38]. It is therefore noteworthy and alarming that at study 
entry our population of cervical cancer survivors report a significant rate of moderate to 
severe depression and anxiety, ranging from 42–49%. It is well-recognized that even 
moderate levels of distress may affect recruitment and retention into clinical trials [39, 40], 
as was the case in our trial [25], or completion of recommended treatment regimens [5, 12, 
13].
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This study contributes new evidence demonstrating validity and reliability of PROMIS 
depression and anxiety short forms in cervical cancer survivors, demonstrates comparability 
of effect sizes to several emotional distress legacy measures, and presents opportunities to 
administer these in static or computer-adaptive testing forms to diverse populations, further 
enhancing feasibility and decreasing burden. A self-assessment tool enabling patients to 
report their emotional distress can provide additional information concerning the disease, 
short and long-term treatment effects, and importantly adjustments in care that can improve 
patient-reported outcomes.
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Highlights:
- PROMIS depression and anxiety short forms reliably and validly assess 
cervical cancer-specific emotional distress.
- PROMIS depression and anxiety short forms perform as well or better than 
legacy measures among cervical cancer survivors.
The depression short form demonstrated sensitivity to change over time.
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Table 1.
Patient-reported emotional distress measures examined
Instrument Number of Items Subdomains
Functional Assessment of Cancer Therapy - Cervical 
Cancer (FACT-Cx)
42 Physical well-being; Social/family well-being; Emotional 
well-being; Functional well-being; Additional concerns
Brief Symptom Inventory - Global Severity Index 
(BSI-GSI)
53 Somatization; Obsessive-compulsive; Interpersonal 
sensitivity; Depression; Anxiety; Hostility; Phobic anxiety; 
Paranoid ideation; Psychoticism
Impact of Event Scale (IES) 22 Intrusion; Avoidance; Hyperarousal
Perceived Stress Scale (PSS) 10 No subdomains
Medical Outcomes Study - Social Support (MOS-SS) 18 Emotional/informational; Tangible; Affectionate; Positive 
social interaction
PROMIS Emotional Distress 15 Anxiety; Depression
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Table 2.
PROMIS emotional distress short form properties at baseline
PROMIS item identifier Floor Ceiling Mean SD Item text
Emotional Distress - Anxiety
EDANX01 1 5 2.196 1.240 In the past 7 days I felt fearful…
EDANX05 1 5 2.396 1.286 In the past 7 days I felt anxious…
EDANX30 1 5 2.660 1.238 In the past 7 days I felt worried…
EDANX40 1 5 1.920 1.133 In the past 7 days I found it hard to focus on anything other than my 
anxiety…
EDANX46 1 5 2.197 1.219 In the past 7 days I felt nervous…
EDANX53 1 5 2.187 1.158 In the past 7 days I felt uneasy…
EDANX54 1 5 2.557 1.223 In the past 7 days I felt tense…
Emotional Distress - Depression
EDDEP04 1 5 1.975 1.123 In the past 7 days I felt worthless…
EDDEP05 1 5 1.803 1.077 In the past 7 days I felt that I had nothing to look forward to…
EDDEP06 1 5 1.876 1.100 In the past 7 days I felt helpless…
EDDEP17 1 5 2.552 1.135 In the past 7 days I felt sad…
EDDEP22 1 5 1.945 1.128 In the past 7 days I felt like a failure…
EDDEP29 1 5 2.591 1.245 In the past 7 days I felt depressed…
EDDEP36 1 5 2.424 1.201 In the past 7 days I felt unhappy…
EDDEP41 1 5 1.926 1.111 In the past 7 days I felt hopeless…
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Table 3:
Descriptive characteristics and baseline legacy measures for study sample (n=204)
N Mean SD
Age at study 204 44.71 9.58
Diagnosis to T1 (mo) 204 19.33 5.41
ED Depression T-Score 203 53.31 9.77
ED Anxiety T-Score 203 53.85 11.40
FACT-CX 203 124.73 24.28
FACT-TOI 200 86.85 17.36
FACT-PWB 201 22.71 5.50
FACT-SWB 203 19.94 5.96
FACT-EWB 204 17.73 4.67
FACT-FWB 204 20.23 6.40
FACT-Additional Concerns 203 44.01 8.26
BSI-GSI Standard Score 204 12.50 11.54
BSI Depression Standard Score 204 54.65 11.46
BSI Anxiety Standard Score 204 46.55 9.93
IES Total 200 18.21 17.90
PSS Total 189 17.86 7.53
SS Total 203 3.84 0.92
Frequency Percent
Race/Ethnicity Caucasian/Non-Hispanic 105 51.5
African-American 4 2.0
Hispanic 83 40.7
Asian/Pacific Islander 11 5.4
Native American 1 0.5
Marital Status Single 31 15.3
Married 129 63.6
Sep/Wid/Div 43 21.1
Income <$15,000 51 29.3
Refused/unknown=29 $15,000-$35,000 32 18.4
$35,000-$55,000 25 14.4
>$55,000 66 37.9
Education < High School 43 21.3
Unknown=2 High School graduate 40 19.8
Some college 56 27.7
College graduate 33 16.3
Graduate/professional 30 14.9
Stage I 147 73.1
II 28 13.9
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N Mean SD
III-IVA 26 12.9
Unknown 3
Treatment Surgery only 100 49.0
Radiation only 15 7.4
Chemo +/− Radiation 89 43.6
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Table 6:
PROMIS Depression and Anxiety over time and Pearson Correlations for change in PROMIS Depression and 
Anxiety with change in legacy measures
Depression T-Score* Anxiety T-Score*
T1 T2 T3 T1 T2 T3
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
PTC 53.7 (9.9) 48.6 (10.1) 48.6 (9.4) 53.8 (11.8) 49.4 (10.0) 48.4 (10.7)
UC 52.8 (9.6) 51.8 (8.9) 51.1 (10.2) 53.9 (11.0) 52.1 (10.1) 51.3 (10.3)
Prevalence of Clinical Depression+ (T-Score>55) Prevalence of Clinical Anxiety+ (T-Score>55)
T1 T2 T3 T1 T2 T3
N (%) N (%) N (%) N (%) N (%) N (%)
PTC 25 (33)a 21 (28) 14 (18) 28 (37)b 21 (28) 24 (32)
UC 37 (51)a 30 (41) 28 (38) 36 (49)b 31 (42) 28 (38)
Pearson Correlations with Change in Depression T-Score Change in Anxiety T-Score
Change in Legacy Measures T2−T1 T3−T1 T2−T1 T3−T1
FACT-Cx T2−T1 −0.35 T2−T1 −0.22
T3−T1 −0.54 T3−T1 −0.27
FACT-TOI T2−T1 −0.25 T2−T1 −0.13
T3−T1 −0.51 T3−T1 −0.22
FACT-EWB T2−T1 −0.39 T2−T1 −0.37
T3−T1 −0.48 T3−T1 −0.40
BSI Depression Standard Score T2−T1 0.41 T2−T1
T3−T1 0.58 T3−T1
BSI Anxiety Standard Score T2−T1 T2−T1 0.41
T3−T1 T3−T1 0.37
*Unadjusted
+
Includes only those completing assessment at all time points (n=149).
aAmong all patients including dropouts (n=203), depression T-score was ≥55 for 48/114 (42%) for PTC and 44/89 (49%) for UC at baseline (T1).
bAmong all patients including dropouts (n=203), anxiety T-score was ≥55 for 52/114 (46%) for PTC and 44/89 (49%) for UC at baseline (T1).
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